scispace - formally typeset
L

Liana Gheorghe

Researcher at Carol Davila University of Medicine and Pharmacy

Publications -  143
Citations -  3351

Liana Gheorghe is an academic researcher from Carol Davila University of Medicine and Pharmacy. The author has contributed to research in topics: Cirrhosis & Internal medicine. The author has an hindex of 24, co-authored 112 publications receiving 2776 citations.

Papers
More filters
Journal ArticleDOI

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Vlad Ratziu, +70 more
- 01 May 2016 - 
TL;DR: A post-hoc analysis of data from trial of patients with NASH showed that elafibranor (120 mg/d for 1 year) resolved NASH without fibrosis worsening, based on a modified definition, in the intention-to-treat analysis and in patients with moderate or severe NASH.
Journal ArticleDOI

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.

A. Sibley, +127 more
TL;DR: The current treatment rate and efficacy are not sufficient to manage the disease burden of hepatitis C virus and alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver‐related deaths from increasing.
Journal ArticleDOI

Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study

Homie Razavi, +114 more
TL;DR: The EU is uniquely poised to eliminate HCV; however, expansion of screening programmes is essential to increase treatment to achieve the WHO targets, and a united effort, grounded in sound epidemiological evidence, will also be necessary.
Journal ArticleDOI

Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.

Sarah Blach, +257 more
TL;DR: In this article , a literature review, Delphi process, and mathematical modelling were used to estimate hepatitis C virus (HCV) prevalence (viraemic infection, defined as HCV RNA-positive cases) and the cascade of care among people of all ages (age ≥ 0 years from birth) for the period between Jan 1, 2015 and Dec 31, 2030.
Journal ArticleDOI

Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe

TL;DR: Findings have implications for meeting WHO targets, with evidence of some countries not following the 2016 hepatitis C virus treatment guidelines by the European Association for the Study of Liver.